Metagenomi, Inc. (MGX)

Metagenomi Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	55.93	44.76	17.2	0.24
Revenue Growth (YoY)	83.36%	160.21%	6978.19%	-
Cost of Revenue	111.35	94.4	43.14	14.48
Gross Profit	-55.42	-49.65	-25.94	-14.24
Selling, General & Admin	33.06	28.85	18.7	9.71
Operating Expenses	33.06	28.85	18.7	9.71
Operating Income	-88.49	-78.49	-44.64	-23.95
Interest Expense	-	-	-0.1	-0.3
Interest & Investment Income	15.41	15.47	3.42	0.04
Other Non Operating Income (Expenses)	-0.19	-0.07	0.2	0
EBT Excluding Unusual Items	-73.27	-63.1	-41.12	-24.2
Gain (Loss) on Sale of Investments	-	2.87	0.09	2.76
Pretax Income	-73.27	-60.23	-41.02	-21.44
Income Tax Expense	1.73	8.03	2.57	-
Net Income	-75	-68.26	-43.59	-21.44
Net Income to Common	-75	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	15	3	3	6
Shares Outstanding (Diluted)	15	3	3	6
Shares Change (YoY)	336.61%	0.15%	-40.27%	-
EPS (Basic)	-5.04	-20.05	-12.82	-3.77
EPS (Diluted)	-5.04	-20.05	-12.82	-3.77
Free Cash Flow	-106.06	-101.22	15.75	21.35
Free Cash Flow Per Share	-7.13	-29.73	4.63	3.75
Gross Margin	-99.09%	-110.93%	-150.81%	-
Operating Margin	-158.21%	-175.38%	-259.53%	-9854.73%
Profit Margin	-134.10%	-152.50%	-253.45%	-8823.87%
Free Cash Flow Margin	-189.63%	-226.17%	91.55%	8787.65%
EBITDA	-83.55	-74.29	-42.91	-23.56
EBITDA Margin	-149.38%	-165.98%	-249.46%	-
D&A For EBITDA	4.94	4.21	1.73	0.39
EBIT	-88.49	-78.49	-44.64	-23.95
EBIT Margin	-158.21%	-175.38%	-259.53%	-

Source: S&P Capital IQ. Standard template. Financial Sources.